Comparative Pharmacology
Head-to-head clinical analysis: DHIVY versus LOGILIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DHIVY versus LOGILIA.
DHIVY vs LOGILIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Lorecivivt, the active component of Logilia, is a small interfering RNA (siRNA) that targets the synthesis of transthyretin (TTR) protein. It binds to a genetically conserved sequence in the 3' untranslated region of mutant and wild-type TTR mRNA, leading to its degradation via RNA interference. This reduces TTR protein production and deposition in tissues.
DHIVY is not a recognized drug. No dosing information available.
100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when CrCl <30 mL/min).
Terminal elimination half-life: 12–15 hours; dose adjustment recommended in renal impairment
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Approximately 60% renal (as unchanged drug), 40% biliary/fecal
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive